Frontlight ResearchEarly access
Not yet taking people in FrancePhase 1/2
Gene therapy tested in children with spinal muscular atrophy and progressive myoclonic epilepsy
Tests a gene therapy given into the spinal fluid of children with SMA-PME.
Key facts
- Who runs it
- Genethon
- Where
- Le Kremlin Bicetre Cedex and Paris, FranceSee the 2 sites
- Trial code
- Registry title
- AAV9-ASAH1 intracisterna magna Gene Therapy (GNT0009) in Patients with Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA - PME)
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 3 people, planned
- Started
- 16 Nov 2026
- Expected to end
- 16 Nov 2031
- Type of study
- Interventional
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with a genetically confirmed diagnosis of spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). They receive a single gene therapy dose into the fluid space at the base of the brain.
- Age
- Up to 17 years.
- Sex
- Males and females can join.
- Disease stage
- Genetically documented SMA-PME. People who have lost all movement and all head and trunk control cannot join.
- Earlier treatment
- Vaccinations must be up to date under the French national schedule (2025). Strong CYP3A4 or P-gp inducer or inhibitor medicines cannot be used at the same time.
- Biomarker or test result
- A documented genetic diagnosis of SMA-PME is needed.
Main reasons for not taking part
- Farber disease
- HIV infection, or active hepatitis B or hepatitis C infection
- Severe intellectual disability (for example IQ below 50)
- Severe breathing problems (for example FVC below 30% predicted, or long-term ventilation)
- Raised pressure in the head, hydrocephalus, or a bleeding risk from clotting problems
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Male or female participants
- Documented genetically SMA-PME diagnosis
- Up-to-date immunization status according to the French national vaccination schedule (2025), including recommended vaccines for age and/or risk groups, notably: hepatitis B, measles-mumps-rubella (MMR), varicella*, hepatitis A (in at-risk populations), Neisseria meningitidis (ACWY + B), Streptococcus pneumoniae, seasonal influenza, SARS-CoV-2, and respiratory syncytial virus (RSV) where indicated
- Ability of the participant and/or legal representatives to confirm the adherence to the clinical trial visit schedule and all protocol requirements
- Effective contraception
Who cannot take part
- Concomitant use of strong CYP3A4 and/or P-glycoprotein (P-gp) inducers or inhibitors
- Presence of any permanent or non-MRI–compatible implants or devices (e.g., metal braces) that preclude safe MRI assessment
- Diagnosis of Farber disease
- Positive serology consistent with human immunodeficiency virus (HIV) infection or evidence of active hepatitis B or hepatitis C infection
- Severely impaired pulmonary function (e.g., FVC <30% predicted) and/or respiratory insufficiency requiring either of the following: (a) non-invasive ventilation for >16 hours per day, or (b) invasive mechanical ventilation via tracheostomy
- Coagulation disorders or clinically significant abnormalities in coagulation parameters that increase the risk of bleeding associated with ICM administration
- Presence of a severe concomitant medical condition or clinically significant abnormal laboratory / imaging findings that, in the opinion of the investigator, may interfere with the course of SMA-PME or place the participant at increased risk of severe complications
- Severe intellectual disability (e.g., intellectual quotient [IQ] < 50)
- Gross Motor Function Classification in Metachromatic Leukodystrophy (GMFC-MLD) score of 6 (loss of any locomotion as well as loss of any head and trunk control)
- Hepatic dysfunction Grade ≥3 as defined by CTCAE criteria
- History or evidence of increased intracranial pressure, hydrocephalus, or need for CSF diversion
Where in France
- Bicetre HospitalLe Kremlin Bicetre Cedex, FranceNot yet recruiting
- Trousseau HospitalParis, FranceNot yet recruiting
About the trial
What the trial wants to find out
To evaluate the safety and tolerability of a single ICM administration of GNT0009 in patients with SMA-PME
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Phase 1/2 Open-Label Trial to Evaluate the Safety, Tolerability, Biological Activity, and Clinical Efficacy of intracisterna Magna administration of an AAV9 Vector Encoding Human ASAH1 (GNT0009) in Patients with Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA-PME)
- Plain-language title
- Gene therapy tested in children with spinal muscular atrophy and progressive myoclonic epilepsyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 November 2026